ClinicalTrials.gg
RecruitingNCT05137119SNAPUpdated May 6, 2026

Staphylococcus Aureus Network Adaptive Platform Trial

A Phase 4 interventional study of Cefazolin and Penicillin in Staphylococcus Aureus Bacteremia, sponsored by University of Melbourne. Recruiting at 161 sites in 13 countries. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Melbourne · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,000
Allocation
Randomized
Sex
All
01

Study summary

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Read the detailed description

Infection of the bloodstream with the bacterium Staphylococcus aureus (Staphylococcus aureus bacteraemia, SAB) is a serious infection that results in 15-30% of affected patients dying within three months of acquiring the infection. Treatment of this infection requires patients to be hospitalised, treated with prolonged antibiotics through an intravenous line, and carefully examined for the occurrence of complications associated with this condition. At present, there are many treatment options in current use, with no clear agreement as to which of these is best. The SNAP trial aims to identify which treatment options for SAB results in the fewest patients dying within the first 90 days after an infection.

In contrast to a conventional clinical trial, the SNAP trial will examine multiple different treatment options at once. Patients will be randomly assigned to different concurrent treatment options currently considered acceptable in routine medical care, but as the trial progresses, more patients will be assigned to treatments that appear to have better outcomes than those with worse outcomes. The trial will adapt to accumulating trial evidence, on a regular basis, by removing treatment options found to be inferior, incorporating new treatment options, and ensuring that all patients in the trial receive the best treatments once they have been identified. Over time, we hope to determine the best combination of treatment options for patients with SAB.

The SNAP Trial infrastructure will also support a number of sub-studies. A list of all active sub-studies can be found on the SNAP website: https://www.snaptrial.com.au/substudies.

02

Conditions studied

  • Staphylococcus Aureus Bacteremia

Keywords

  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Methicillin-susceptible Staphylococcus aureus (MSSA)
  • Penicillin-susceptible Staphylococcus aureus (PSSA)
  • Staphylococcus aureus
  • S. aureus
  • Staph Aureus Bacteremia (SAB)
03

In context

Staphylococcal Infections

305 studies on the registry are indexed under Staphylococcal Infections; 36 are open to participants now.

This study's planned enrollment of 8,000 is above the median of 124 across 199 interventional studies indexed under Staphylococcal Infections.

Browse Staphylococcal Infections studies →

Lead sponsor

University of Melbourne is the lead sponsor of 87 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

PLATFORM Inclusion Criteria:

Patients must fulfil all of the following criteria to be eligible to enter the SNAP trial:

  1. Staphylococcus aureus complex grown from ≥1 blood culture
  2. Admitted to a participating hospital at the time of eligibility assessment (OR if patient has died, they were admitted to this site anytime from the time of blood culture collection until the time of eligibility assessment)

PLATFORM Exclusion Criteria:

Potentially eligible participants meeting any of the following criteria at the time of eligibility assessment for platform entry will be excluded from the randomised platform (but may still participate in the registry):

  1. Time of anticipated platform entry is greater than 72 hours post collection of the index blood culture (Where the time of culture collection is not recorded, the time of laboratory registration of the sample will be used as an alternative)
  2. Polymicrobial bacteraemia, defined as more than one organism (at species level) in the index blood cultures OR in any subsequent blood culture reported between the collection of the index blood culture and platform eligibility assessment, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician.
  3. Known previous participation in the randomised SNAP platform
  4. Known positive blood culture for S. aureus (of the same silo: PSSA, MSSA or MRSA) between 72 hours and 180 days prior to the time of eligibility assessment
  5. Treating team deems enrolment in the study is not in the best interest of the patient
  6. Treating team believes that death is imminent and inevitable
  7. Patient is for end-of-life care and antibiotic treatment is considered not appropriate
  8. Patient \<18 years of age and paediatric recruitment not approved at recruiting site
  9. Patient has died since the collection of the index blood culture

To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)

ADJUNCTIVE TREATMENT DOMAIN

Inclusion Criteria:

  1. All participants that met the PLATFORM eligible are eligible to be included in this domain unless they meet any of the following exclusions listed.
  2. Patients are eligible for this domain regardless of S. aureus susceptibility testing results to clindamycin.

Exclusion criteria:

1. Previous type 1 reaction to lincosamides 2. Currently receiving clindamycin (lincomycin) or linezolid which cannot be ceased or substituted 3. Necrotising fasciitis 4. Current C. difficile associated diarrhoea (any severity) 5. Current severe diarrhoea from any cause (defined as Grade 3 or higher) 5. Known CDAD (C.Difficile Associated Diarrhoea) in the past 3 months, or CDAD relapse in the past 12 months 6. At the time of domain eligibility assessment, more than 4 hours has elapsed since platform entry 7. Treating clinician deems enrolment in this domain is not in the best interest of the patient

PSSA, MSSA TREATMENT DOMAIN (backbone)

Inclusion Criteria:

  1. For PSSA silo: Index blood culture isolate is penicillin-susceptible as per the Microbiology Appendix. In short, this will require phenotypic disc testing with EUCAST (a P1 disc diffusion with zone >=26mm OR a P1 disc diffusion with zone >=26mm and the zone edge is NOT sharp) OR CLSI (a P10 disc diffusion) defined criteria.
  2. For MSSA silo: Index blood culture isolate is methicillin-susceptible as per the Microbiology Appendix.

Note that where trial sites are not testing for penicillin-susceptibility, patients with MSSA/PRSA can be included in the MSSA silo, but those with MSSA/PSSA (but not confirmed with a P-disc) will be excluded from the backbone domain. The rationale for this is that patients with MSSA but not tested with a P-disc may be truly PSSA (with no blaZ). If the cefazolin inoculum effect (CIE) is a entity, then including patients with an organism without blaZ (and hence cannot have a CIE phenotype), will bias towards non-inferiority of cefazolin compared to (flu)cloxacillin.

For PSSA, the requirement for laboratories to use an accredited phenotypic test for a penicillin-susceptible phenotype, is to ensure clinical safety according to internationally accepted guidelines. The automated antimicrobial susceptibility testing, and other phenotypic tests, have poor sensitivity for detection of blaZ compared to a gold standard of blaZ PCR. Therefore, patients could be placed at risk of treatment with benzylpenicillin when the infecting isolate is actually blaZ positive, unless these guidelines are followed.

Exclusion Criteria (PSSA \& MSSA):

  1. >72 hours have elapsed since the collection of the index blood culture (i.e. the time of collection of the first positive blood culture from the patient during this episode)
  2. History of type I hypersensitivity reaction (i.e. anaphylaxis or angioedema) to any penicillin or cephalosporin
  3. History of severe delayed reaction (e.g. allergic interstitial nephritis, cutaneous vasculitis, Stevens-Johnson, DRESS, etc.) to any penicillin or cephalosporin
  4. PSSA silo: Non-severe rash to any penicillin (unless patient has been subsequently de-labelled; this criteria does not include criteria 2 and 3 above), or MSSA silo: Non-severe rash to cefazolin or any penicillin (unless patient has been subsequently de-labelled); (Nausea, diarrhoea, headache, and other non-specific symptoms are NOT allergies, they are drug intolerance, and they are not exclusion criteria. Similarly, a vague history of an allergy of unclear nature, or a family history of allergy are not exclusions.)
  5. Treating team deems enrolment in this domain is not in the best interest of the patient
  6. Currently receiving maintenance dialysis (haemodialysis or peritoneal dialysis); (Acute renal replacement therapy (including CRRT, haemodialysis or peritoneal dialysis) are not exclusions. Such patients are eligible as long as appropriate vascular access is available or can be arranged.)
  7. Polymicrobial bacteraemia (defined as more than one organism [at species level] in blood cultures, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician) reported between collection of the index blood culture and backbone domain eligibility assessment
  8. Patient currently being treated with a systemic antibacterial agent that cannot be ceased or substituted for interventions allocated within the platform (unless antibiotic is listed in Table 1 of the DSA, which specifies allowed antibiotics with limited absorption from the gastrointestinal tract or negligible antimicrobial activity against S. aureus)

MRSA TREATMENT DOMAIN (backbone)

Inclusion Criteria:

1. MRSA confirmed microbiologically

Exclusion Criteria:

  1. Time to allocation reveal is >72 hours from time of index blood culture collection
  2. Severe allergy to any beta-lactam (including cefazolin) Immediate severe allergy: Anaphylaxis/angioedema Severe delayed allergy: Severe cutaneous adverse reaction (SCAR; including Steven Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) and acute generalised exanthematous pustulosis (AGEP)), severe drug induced liver injury, proven allergic interstitial nephritis, immune-mediated haemolytic anaemia and other severe cytopenia.
  3. Non-severe rash to cefazolin Nausea, diarrhoea, headache and other non-specific symptoms are NOT allergies, they are drug intolerance, and they are not exclusion criteria. Similarly, a vague history of an allergy of unclear nature, or a family history of allergy are not exclusions.)

3. Severe allergy or non-severe rash to both vancomycin AND daptomycin Vancomycin infusion reaction (formerly known as "red man syndrome") is due to direct histamine release and is not generally an allergy, and therefore is not considered an exclusion.

5. Treating team deems enrolment in the domain is not in the best interest of the patient 6. Polymicrobial bacteraemia (defined as more than one organism [at species level] in blood cultures, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician) reported between collection of the index blood culture and backbone domain eligibility assessment.

7. Patient currently being treated with a systemic antibacterial agent that cannot be ceased or substituted for interventions allocated within the platform (unless antibiotic is listed in Table 1 of the DSA, which specifies allowed antibiotics with limited absorption from the gastrointestinal tract or negligible antimicrobial activity against S. aureus)

EARLY ORAL SWITCH DOMAIN

Inclusion Criteria:

Day 7 (+/- 2 days):

  1. Clearance of SAB by platform Day 2: blood cultures negative for S. aureus from platform Day 2 onwards AND no known subsequent positive blood cultures
  2. Afebrile (\<37.8°C) for the past 72 hours (at time of judging eligibility)
  3. Primary focus is either line related (either central or peripheral IV cannula) or skin and soft tissue, AND source control achieved (for 'line-related' this means line removed; for 'skin and soft tissue' means site PI considers source control to have been achieved and any abscess more than 2cm diameter has been drained)
  4. No evidence of foci (on clinical or radiological examination, but radiological imaging is not required to exclude metastatic foci if not clinically indicated)

Day 14 (+/- 2 days):

  1. Clearance of SAB by platform Day 5: blood cultures negative for S. aureus from platform Day 5 (+/-1 day) AND no known subsequent positive blood cultures. If the most recent blood culture from Day 2-4 is negative for S. aureus, blood cultures do not need to be repeated on Day 5 to fulfil eligibility criteria (Day 5 blood cultures will be assumed to be negative in this situation)
  2. Afebrile (\<37.8°C) for the past 72 hours (at time of judging eligibility)
  3. Site Principal Investigator has determined that source control is adequate

Exclusion Criteria:

When judging eligibility at platform Day 7 (+/- 2 days) and at Day 14 (+/- 2 days), exclusion criteria are:

  1. Adherence to oral agents unlikely (as judged by site PI in consultation with the treating team)
  2. Unreliable gastrointestinal absorption (e.g. vomiting, diarrhoea, nil by mouth, anatomical reasons)
  3. There are no appropriate oral antibiotics due to , drug availability, or antibiotic resistance
  4. Ongoing IV therapy unsuitable e.g. no IV access
  5. Clinician deems not appropriate for early oral switch
  6. Patient no longer willing to participate in domain In the lead-up to judging eligibility, it may be helpful to discuss with the patient the potential for continued IV treatment versus oral switch, to allow hospital discharge planning
  7. Clinical team deems that sufficient duration of antibiotic therapy has already been provided

Exclusions when judging eligibility for early oral switch at trial Day 7 (+/- 2 days):

  1. Presence of prosthetic cardiac valve, pacemaker or other intracardiac implant
  2. Presence of intravascular clot, graft, or other intravascular prosthetic material Intravascular clot excludes superficial peripheral IV line-related thrombophlebitis. Intravascular prosthetic material excludes coronary artery stents)
  3. Intravascular/intracardiac infections (e.g. endocarditis, mycotic aneurysm)
  4. Presence of other intracardiac abnormalities felt to put patient at increased risk of endocarditis (e.g., bicuspid aortic valve)

PET/CT DOMAIN

Inclusion Criteria:

  1. PET/CT participating site
  2. Patient is accessible for PET/CT - a patient is considered accessible if the site team are able to access the participant medical records, arrange for a PET/CT scan for the patient, and discuss this domain with the patient and their treating healthcare providers.

Exclusion Criteria:

  1. Pregnant - patients of should be assessed for pregnancy status and a pregnancy test performed (if not performed within the past 10 days)
  2. Currently breastfeeding
  3. \< 18 years of age
  4. Patient has had PET/CT in the past 7 days
  5. Patient needs PET/CT in the next 7 days (in the opinion of the clinical team, at the time of eligibility assessment)
  6. Clinically unstable for PET/CT (as judged by the treating clinical team, taking into account need for organ support (including inotropes) and capacity to lie flat for the PET/CT)
  7. Contraindication to PET/CT (e.g., claustrophobia, persistently elevated blood sugar levels [>12.5mmol/L] that cannot be corrected).
  8. Patient no longer willing to participate in the domain - in the days leading up to judging eligibility, it may be helpful to discuss with the patient the potential for PET/CT vs no PET/CT to allow imaging planning
  9. Clinician deems participation in this domain is not in the patient's best interests
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
8,000 participants (estimated)

Study arms

  • No intervention
    Methicillin-resistant staphylococcus aureus (MRSA) - Standard Therapy Arm (backbone therapy)

    Vancomycin or Daptomycin - Standard Therapy Arm Either intravenous vancomycin dosed as per Australian Therapeutic Guidelines: This includes a loading dose of 25 mg/kg (up to 3000mg) if considered appropriate by the treating clinician, initial maintenance dosing at 15-20 mg/kg q12h, with subsequent adjustment to maintain area under the concentration-time curve (AUC) of 400 to 600 mg.hr/L OR trough levels at 10-20 mg/L, and the initial level taken 48-72 hours after the initiation of the first dose. Daptomycin 8-10mg/kg per day intravenously. The choice of vancomycin or daptomycin will be at the clinician's discretion. Dosing will be based on renal function.

  • Experimental
    Methicillin-resistant staphylococcus aureus (MRSA) - Standard + B-Lactam Arm (backbone therapy)

    Vancomycin or Daptomycin (Standard Therapy) + Beta-Lactam (β-lactam) Arm In addition to standard treatment an intravenous β-lactam will be added for the first 7 calendar days following randomisation (day 1 being the day of randomisation - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous cefazolin 2g every 8 hours. For patients with renal impairment the intravenous cefazolin administration doses will be adjusted.

    Drug: Cefazolin · Drug: Vancomycin

  • No intervention
    Methicillin-susceptible staphylococcus aureus (MSSA) - Standard Therapy Arm (backbone therapy)

    Flucloxacillin or cloxacillin - Standard Therapy Arm Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted.

  • Experimental
    Methicillin-susceptible staphylococcus aureus (MSSA) - Interventional Arm (backbone therapy)

    Cefazolin - Interventional Arm Intravenous cefazolin 2g every 6 or 8 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous cefazolin administration dose will be adjusted.

    Drug: Cefazolin

  • No intervention
    Penicillin-susceptible staphylococcus aureus (PSSA) - Standard Therapy Arm (backbone therapy)

    Flucloxacillin or cloxacillin - Standard Therapy Arm Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted.

  • Experimental
    Penicillin-susceptible staphylococcus aureus (PSSA) - Interventional Arm (backbone therapy)

    Benzylpenicillin - Interventional Arm Intravenous benzylpenicillin 1.8g (3 million units) every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with critical illness the intravenous benzylpenicillin administration doses will be adjusted.

    Drug: Penicillin

  • No intervention
    No adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm

    No adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA Participants with either MRSA or MSSA or PSSA will have no adjunctive therapy in combination with their backbone therapy arm.

  • Experimental
    Adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm

    Adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA Intravenous clindamycin (or lincomycin) 600mg every 8 hours from platform day 1 to day 5. No dosage adjustment is needed to renal impairment.

    Drug: Clindamycin

  • No intervention
    Continue intravenous antibiotic therapies (backbone +/- adjunctive therapy) - standard of care arm

    Backbone therapy arm for MRSA or MSSA or PSSA +/- adjunctive therapy will continue on intravenous antibiotic treatment for the length of time as per usual standard of care. Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised if not eligible then eligibility will be assess again at Day 14(+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain.

  • Experimental
    Switch to oral antibiotics at trial day 7 (+/- 2 days) or Day 14 (+/- 2 days) if eligible.

    Switch from intravenous backbone antibiotic for MRSA or MSSA or PSSA to oral antibiotics at the treating clinicians discretion on trial Day 7 (+/- 2 days) or trial Day 14 (+/- 2 days). Participants eligibility is assessed at Day 7 (+/- 2 days). If eligible will be randomised, if not eligible then eligibility will be assessed again at Day 14 (+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain.

    Other: Effectiveness of early switch to oral antibiotics

  • No intervention
    No PET/CT scan - standard of care arm

    Participants will not receive a PET/CT scan, in addition to their allocated treatment interventions. Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised. If eligibility is not met then participant is excluded from this domain.

  • Experimental
    PET/CT scan at trial day 7 (+/- 2 days) if eligible

    Participant will receive a PET/CT scan at Day 5-12, in addition to their allocated treatment interventions. Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised. If eligibility is not met then participant is excluded from this domain.

    Radiation: Whole body FDG PET/CT Imaging

Interventions

  • Cefazolin

  • DrugPenicillin

    Drug pages: PenicillinsStudies of PenicillinsPenicillins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Penicillin AntibioticStudies of Penicillin AntibioticPenicillin Antibiotic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Penicillin GStudies of Penicillin GPenicillin G pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    benzylpenicillin

    Also known as: Benzylpenicillin, Penicillin G

  • Clindamycin

    Also known as: Lincomycin

  • Vancomycin or Daptomycin

    Also known as: Daptomycin

  • OtherEffectiveness of early switch to oral antibiotics

    This involves testing a strategy rather than individual antibiotic agents

  • RadiationWhole body FDG PET/CT Imaging

    Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.

06

What researchers measure

Primary outcomes

  1. All-cause mortality at 90 days after platform entry

    The primary endpoint for all cells and domains will be all-cause mortality at 90 days after platform entry. The primary endpoint will be determined through a search of hospital databases for a record of a participant's death, or follow-up contact with the participant's community healthcare provider, or follow-up contact with the patient or their nominated carer, or linkage with death registries.

    Time frame: From randomisation (day 1) until day 90

Secondary outcomes

  1. Core1: All-cause mortality at 14, 28 and 42 days after platform entry

    Determined through a search of hospital databases for a record of a participant's death, or follow-up contact with the participant's community healthcare provider, or follow-up contact with the patient or their nominated carer, or linkage with death registries.

    Time frame: From randomisation (day 1) until day 14, 28, and 42

  2. Core2: Duration of survival censored at 90 days after platform entry

    Determined through a search of hospital databases for a record of a participant's death, or follow-up contact with the participant's community healthcare provider, or follow-up contact with the patient or their nominated carer, or linkage with death registries.

    Time frame: From randomisation (day 1) until day 90

  3. Core3: Length of stay of acute index inpatient hospitalisation for those surviving until discharge from acute inpatient facilities (excluding HITH/COPAT/OPAT/rehab).

    Acute index hospitalisation is defined as continuous hospital admission to one or more acute inpatient facilities for the index episode. This does not include HITH/OPAT/COPAT and stepdown inpatient rehabilitation/post-acute care. It does include admission to acute care hospitals immediately preceding and following those at the enrolling site.

    Time frame: From randomisation (day 1) until discharge from acute inpatient facilities, truncated at 90 days.

  4. Core4: Length of stay of total index hospitalisation for those surviving until hospital discharge (including HITH/COPAT/OPAT/rehab)

    Total index hospitalisation is defined as continuous hospital admission to one or more inpatient facilities for the index episode, including HITH/OPAT/COPAT and stepdown inpatient rehabilitation/post-acute care (if continuous with the initial inpatient admission). It includes admission to acute care hospitals immediately preceding and following those at the enrolling site.

    Time frame: From randomisation (day 1) to discharge from total index hospitalisation, truncated at 90 days

  5. Core5: Time to being discharged alive from the total index hospitalisation (including HITH/COPAT/OPAT/rehab) truncated at 90 days after platform entry

    and all deaths within 90 days will be considered '90 days'

    Time frame: From randomisation (day 1) to discharge from total index hospitalisation, truncated at 90 days

  6. Core6: Microbiological treatment failure defined as positive sterile site culture for S. aureus [of the same silo as the index isolate between 14 and 90 days after platform entry).

    A sterile site means any sites deep to the skin and skin structures, including deep visceral and musculoskeletal abscesses that have been obtained in a sterile manner.

    Time frame: From day 14 until day 90

  7. Core7: Diagnosis of new foci between 14 and 90 days after platform entry.

    The presence of new foci will be determined by the site investigator and can incorporate clinical, radiological, microbiological and pathological findings.

    Time frame: From day 14 until day 90

  8. Core8: C. difficile diarrhoea as determined by a clinical laboratory in the 90 days following platform entry for participants ≥2 years of age.

    This means a stool submitted to a clinical laboratory has tested positive for C. difficile toxin or toxin gene.

    Time frame: From randomisation (day 1) until day 90

  9. Core9: Serious adverse reactions (SARs) in the 90 days following platform entry

    SARs defined only as serious events that are attributable to one or more randomised study interventions

    Time frame: From randomisation (day 1) until day 90

  10. Core10: Health economic costs as detailed in the health ecnomics appendix.

    Including hospital length of stay, readmissions, and patient employment status.

    Time frame: From randomisation (day 1) until day 90

  11. Core11: Proportion of participants who have returned to their usual level of function at day 90.

    Determined by whether the modified functional bloodstream infection score (FBIS) remained the same or improved between baseline and 90 days after platform entry where baseline=best score within the 4 weeks prior to platform entry.

    Time frame: From randomisation (day 1) until day 90

  12. Core12: Desirability of outcome ranking 1 (DOOR1; modified Antibiotic Resistance Leadership Group version)

    See Core Protocol; unable to insert DOOR1 table

    Time frame: From randomisation (day 1) until day 90

  13. Core13: Desirability of outcome ranking 2 (DOOR2; SNAP version)

    See Core Protocol; unable to insert DOOR2 table

    Time frame: From randomisation (day 1) until day 90

  14. Core14: Total number of antibiotic days (IV and/or oral/enteral) in the 90 days following platform entry.

    All antibiotics should be included, not only those intended for treatment of S. aureus bacteraemia. It also includes prophylactic dose antibiotics (e.g., prophylactic dose trimethoprim-sulfamethoxazole). All days on which any antibiotic dose is received should be counted - i.e. we are counting the number of whole or part days on which any antibiotics are received (not the number of defined daily doses of antibiotics). Topical, inhaled or other routes of administration besides IV or oral/enteral should not be counted.

    Time frame: From randomisation (day 1) until day 90

  15. Core15: Days alive and free of antibiotics in the 90 days following platform entry.

    All antibiotics should be included, not only those intended for treatment of S. aureus bacteraemia. It also includes prophylactic dose antibiotics (e.g., prophylactic dose trimethoprim-sulfamethoxazole). All days on which any antibiotic dose is received should be counted - i.e. we are counting the number of whole or part days on which any antibiotics are received (not the number of defined daily doses of antibiotics). Topical, inhaled or other routes of administration besides IV or oral/enteral should not be counted.

    Time frame: From randomisation (day 1) until day 90

07

Study locations

126 of 161 sites recruiting
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
    Recruiting
  • Canberra Hospital
    Garran, Australia Capital Territory 2605, Australia
    Recruiting
    • Heather Wilson · Principal investigator
  • Blacktown Hospital
    Blacktown, New South Wales 2148, Australia
    Recruiting
    • Ravindra Dotel · Principal investigator
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
    Recruiting
    • Sebastian VanHal · Principal investigator
  • Concord Repatriation and General Hospital
    Concord, New South Wales 2139, Australia
    Recruiting
    • Genevieve McKew · Principal investigator
    • Timothy Gray · Sub investigator
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
    • Gail Matthews · Principal investigator
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
    Recruiting
    • Archana Sud · Principal investigator
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
    Not yet recruiting
    • Katy Lai · Principal investigator
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
    Recruiting
    • Hong Foo · Principal investigator
  • John Hunter Hospital
    New Lambton Heights, New South Wales 2305, Australia
    Recruiting
    • Brian Chong · Principal investigator
  • John Hunter Children's Hospital
    Newcastle, New South Wales 2305, Australia
    Recruiting
    • Coen Butters · Principal investigator
  • Orange Health Service
    Orange, New South Wales 2800, Australia
    Recruiting
    • Jacob Williams · Principal investigator
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
    Recruiting
    • Trine Gulholm · Principal investigator
  • Sydney Children's Hospital
    Randwick, New South Wales 2031, Australia
    Recruiting
    • Brendan McMullan · Principal investigator
  • The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Philip Britton · Principal investigator
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Matthew O'Sullivan · Principal investigator
  • Wollongong Hospital
    Wollongong, New South Wales 2500, Australia
    Recruiting
    • Niladri Ghosh · Principal investigator
  • Royal Darwin Hospital
    Tiwi, Northern Territory 0811, Australia
    Recruiting
    • Jane Davies · Principal investigator
    • Josh Francis · Sub investigator
    • Kate Proudmore · Sub investigator
  • Sunshine Coast University Hospital
    Birtinya, Queensland 4575, Australia
    Recruiting
    • David Sowden · Principal investigator
    • Shradha Subedi · Sub investigator
  • Cairns Hospital
    Cairns, Queensland 4870, Australia
    Recruiting
    • Simon Smith · Principal investigator
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
    Recruiting
    • Bridget Barber · Principal investigator
  • Ipswich Hospital
    Ipswich, Queensland 4305, Australia
    Recruiting
    • John Woodford · Principal investigator
  • Logan Hospital
    Meadowbrook, Queensland 4131, Australia
    Not yet recruiting
    • Vichitra Sukumaran · Principal investigator
  • Redcliffe Hospital
    Redcliffe, Queensland 4020, Australia
    Recruiting
    • Kevin O'Callaghan · Principal investigator
  • Robina Hospital
    Robina, Queensland 4226, Australia
    Recruiting
    • Peter Simos · Principal investigator
  • Queensland Children's Hospital
    South Brisbane, Queensland 4101, Australia
    Recruiting
    • Clare Nourse · Principal investigator
  • Gold Coast University Hospital
    Southport, Queensland 4215, Australia
    Recruiting
    • Peter Simos · Principal investigator
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
    Not yet recruiting
    • Andrew Henderson · Principal investigator
  • Lyell McEwin Hospital
    Adelaide, South Australia 5112, Australia
    Recruiting
    • Rory Hannah · Principal investigator
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
    Recruiting
    • Nicholas Anagnostou · Principal investigator
  • Women and Children's Hospital
    North Adelaide, South Australia 5006, Australia
    Not yet recruiting
    • Michael Stark · Principal investigator
  • Women's and Children's Hospital
    North Adelaide, South Australia 5006, Australia
    Not yet recruiting
    • Nan Vasilunas · Principal investigator
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
    Not yet recruiting
    • Peter Leung · Principal investigator
  • Launceston Hospital
    Launceston, Tasmania 7250, Australia
    Recruiting
    • Ali Trad · Principal investigator
  • Grampians Health
    Ballarat, Victoria 3350, Australia
    Recruiting
    • Robert Commons · Principal investigator
  • Bendigo Health
    Bendigo, Victoria 3550, Australia
    Recruiting
    • Andrew Mahony · Principal investigator
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
    Recruiting
    • Stephen Guy · Principal investigator
  • Monash Children's Hospital
    Clayton, Victoria 3168, Australia
    Not yet recruiting
    • Jeremy Carr · Principal investigator
  • Monash Health - Monash Medical Centre & Jesse McPherson Private Hospital
    Clayton, Victoria 3168, Australia
    Recruiting
    • Ben Rogers · Principal investigator
  • Western Health - Footscray, Joan Kirner & Sunshine Hospitals
    Footscray, Victoria 3011, Australia
    Recruiting
    • Adrian Tramontana · Principal investigator
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
    Not yet recruiting
    • Kasha Singh · Principal investigator
  • Barwon Health - University Hospital Geelong
    Geelong, Victoria 3220, Australia
    Recruiting
    • Eugene Athan · Principal investigator
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
    Recruiting
    • Natasha Holmes · Principal investigator
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
    • James McMahon · Contact
    • James McMahon · Principal investigator
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
    Recruiting
    • Justin Denholm · Principal investigator
  • Royal Children's Hospital Melbourne
    Parkville, Victoria 3052, Australia
    Recruiting
    • Amanda Gwee · Principal investigator
  • Goulburn Valley Health
    Shepparton, Victoria 3630, Australia
    Completed

    Not enrolling at this site — choose another above.

  • La Trobe Regional Hospital
    Traralgon, Victoria 3844, Australia
    Not yet recruiting
    • Zaal Meher-Homji · Principal investigator
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
    Recruiting
    • Owen Robinson · Principal investigator
  • Perth Children's Hospital
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Asha Bowen · Principal investigator
    • Anita Campbell · Sub investigator
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
    Recruiting
    • Owen Robinson · Principal investigator
  • Armadale Hospital
    Perth, Western Australia 6112, Australia
    Recruiting
    • David New · Principal investigator
  • Peter Lougheed Centre
    Calgary, Alberta T1Y 6J4, Canada
    Recruiting
    • Ranjani Somayaji · Principal investigator
  • Foothills Medical Center
    Calgary, Alberta T2N4Z6, Canada
    Recruiting
    • Ranjani Somayaji · Principal investigator
  • Rockyview Hospital
    Calgary, Alberta T2V 1P9, Canada
    Recruiting
    • Ranjani Somayaji · Principal investigator
  • South Health Campus
    Calgary, Alberta T3M 1M4, Canada
    Recruiting
    • Ranjani Somayaji · Principal investigator
  • University of Alberta Hospital
    Edmonton, Alberta T6G2B7, Canada
    Recruiting
    • Stephanie Smith · Principal investigator
  • Richmond Hospital
    Richmond, British Columbia V6X1A2, Canada
    Recruiting
    • Clement Kwok · Principal investigator
  • Fraser Health Authority - Surrey Memorial Hospital
    Surrey, British Columbia, Canada
    Recruiting
    • Kevin Afra · Principal investigator
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z1M9, Canada
    Recruiting
    • Jennifer Grant · Principal investigator
  • St. Boniface Hospital
    Winnipeg, Manitoba R2H 2A6, Canada
    Recruiting
    • Terry Wuerz · Principal investigator
  • Health Sciences Centre Winnipeg
    Winnipeg, Manitoba R3A1R9, Canada
    Recruiting
    • Terry Wuerz · Principal investigator
  • Grace Hospital
    Winnipeg, Manitoba R3J 3M7, Canada
    Recruiting
    • Terry Wuerz · Principal investigator
  • Eastern Health - Health Sciences Centre (Memorial University)
    St. John's, Newfoundland and Labrador A1B3V6, Canada
    Recruiting
    • Peter Daley · Principal investigator
  • Eastern Regional Health Authority - St. Clare's Mercy Hospital
    St. John's, Newfoundland and Labrador, Canada
    Recruiting
    • Peter Daley · Principal investigator
  • Toronto East Health Network - Michael Garron Hospital
    East York, Ontario M4C3E7, Canada
    Recruiting
    • Christopher Kandel · Principal investigator
  • University Health Network - Toronto General Hospital
    East York, Ontario M5G2C4, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Hamilton Health Sciences - Hamilton General Hospital
    Hamilton, Ontario L8P1A2, Canada
    Recruiting
    • Dominik Mertz · Principal investigator
  • Hamilton Health Sciences - Juravinski Hospital
    Hamilton, Ontario, Canada
    Recruiting
    • Dominik Mertz · Principal investigator
  • Kingston Health Sciences Centre - Kingston General Hospital
    Kingston, Ontario K7L2V7, Canada
    Recruiting
    • Anthony Bai · Principal investigator
  • London Health Sciences Centre - University Hospital, LHSC
    London, Ontario, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Niagara Health - Niagara Falls Site
    Niagara Falls, Ontario, Canada
    Recruiting
    • David McCullagh · Principal investigator
  • The Ottawa Hospital - Civic Campus
    Ottawa, Ontario K1H8L6, Canada
    Recruiting
    • Derek MacFadden · Principal investigator
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario, Canada
    Recruiting
    • Derek MacFadden · Principal investigator
  • Sault Area Hospital
    Sault Ste. Marie, Ontario P6B 0A8, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Niagara Health - St. Catharines Site
    St. Catharines, Ontario L2S 0A9, Canada
    Recruiting
    • David McCullagh · Principal investigator
  • Unity Health - St Michael's Hospital
    Toronto, Ontario M1L 1W1, Canada
    Recruiting
    • Matthew Muller · Principal investigator
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N3M5, Canada
    Recruiting
    • Nick Daneman · Principal investigator
  • Sinai Heath System - Mount Sinai Hospital
    Toronto, Ontario M5G1X5, Canada
    Recruiting
    • Jennie Johnstone · Principal investigator
  • Unity Health Toronto - St Joseph's Health Centre
    Toronto, Ontario, Canada
    Recruiting
    • Kevin Schwarz · Principal investigator
  • University Health Network - Toronto Western Hospital
    Toronto, Ontario, Canada
    Completed

    Not enrolling at this site — choose another above.

  • CISSS - Hôpital Cité-de-la-Santé Hospital
    Laval, Quebec, Canada
    Recruiting
    • Stephanie Castonguay · Principal investigator
  • Jewish General Hospital
    Montreal, Quebec H3T1E2, Canada
    Recruiting
    • Leighanne Parkes · Principal investigator
  • McGill University Health Centre - Montral General Hospital
    Montreal, Quebec H4A3J1, Canada
    Recruiting
    • Matthew Cheng · Principal investigator
  • McGill University Health Centre - Montreal Children's Hospital
    Montreal, Quebec, Canada
    Not yet recruiting
    • Jesse Pappenburg · Principal investigator
  • McGill University Health Centre - Royal Victoria Hospital
    Montreal, Quebec, Canada
    Recruiting
    • Matthew Cheng · Principal investigator
  • Hôpital Régional de Saint Jérôme
    Saint-Jérôme, Quebec J7Z5T3, Canada
    Recruiting
    • Sébastien Poulin · Principal investigator
  • University of Sherbrooke Health Centre - Hospital Fleurimont
    Sherbrooke, Quebec J1H 5H3, Canada
    Recruiting
    • Francois Lamontagne · Principal investigator
  • University of Sherbrooke Health Centre - Hotel Dieu
    Sherbrooke, Quebec, Canada
    Recruiting
    • Francois Lamontagne · Principal investigator
  • CHU de Rennes - Hôpital Pontchaillou
    Rennes, France
    Recruiting
    • David Luque Paz · Principal investigator
  • Charité University Hospital Berlin
    Berlin, Germany
    Recruiting
    • Miriam Stegemann · Principal investigator
  • University Hospital Carl Gustav Carus Dresden
    Dresden, Germany
    Recruiting
    • Katja de With · Principal investigator
  • University Medical Centre Freiburg
    Freiburg im Breisgau, Germany
    Recruiting
    • Siegbert Richard Rieg · Principal investigator
  • Otto-von-Guericke-university Magdeburg
    Magdeburg, Germany
    Recruiting
    • Achim Kaasch · Principal investigator
  • Rambam Health Care Campus
    Haifa, 310960, Israel
    Recruiting
    • Mical Paul · Principal investigator
  • Beilinson Hospital
    Petah Tikva, 49100, Israel
    Recruiting
    • Noa Eliakim-Raz · Principal investigator
  • Schneider Hospital
    Petah Tikva, Israel
    Recruiting
    • Oded Scheureman · Principal investigator
  • Sheba Medical Centre
    Ramat Gan, 49100, Israel
    Recruiting
    • Dafna Yahav · Principal investigator
  • Science Tokyo University Hospital
    Ichikawa, Chiba 272-0827, Japan
    Recruiting
    • Principal Investigator Yoshiaki Gu · Contact
  • Jeroen Bosch Hospital
    's-Hertogenbosch, Netherlands
    Recruiting
    • Thijs ten Doesschate · Principal investigator

Showing the first 100 of 161 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, Goodman AL, Heriot GS, Lee TC, Lewis RJ, Lye DC, Mahar RK, Marsh J, McGlothlin A, McQuilten Z, Morpeth SC, Paterson DL, Price DJ, Roberts JA, Robinson JO, van Hal SJ, Walls G, Webb SA, Whiteway L, Yahav D, Davis JS; Staphylococcus aureus Network Adaptive Platform (SNAP) Study Group. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. Clin Infect Dis. 2022 Nov 30;75(11):2027-2034. doi: 10.1093/cid/ciac476. PubMed 35717634 ↗
  • Symons TJ, Straiton N, Gagnon R, Littleford R, Campbell AJ, Bowen AC, Stewart AG, Tong SYC, Davis JS. Consumer perspectives on simplified, layered consent for a low risk, but complex pragmatic trial. Trials. 2022 Dec 28;23(1):1055. doi: 10.1186/s13063-022-07023-z. PubMed 36578070 ↗
  • Malhame I, Hardy E, Cheng MP, Tong SY, Bowen AC. Walking the walk to include pregnant participants in non-obstetric clinical trials: Insights from the SNAP Trial. Obstet Med. 2023 Mar;16(1):3-4. doi: 10.1177/1753495X231163351. Epub 2023 Mar 22. No abstract available. PubMed 37139509 ↗
  • Henderson A, Cheng MP, Chew KL, Coombs GW, Davis JS, Grant JM, Gregson D, Giulieri SG, Howden BP, Lee TC, Nguyen V, Mora JM, Morpeth SC, Robinson JO, Tong SYC, Van Hal SJ; Microbiology Working Group of the Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group. A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus. J Antimicrob Chemother. 2023 Jun 1;78(6):1499-1504. doi: 10.1093/jac/dkad116. PubMed 37071589 ↗
  • de Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, Hensgens M, Kalimuddin S, Lee TC, Legg A, Mahar RK, Marks M, Marsh J, McGlothin A, Morpeth SC, Sud A, Ten Oever J, Yahav D, Bonten M, Bowen AC, Daneman N, van Hal SJ, Heriot GS, Lewis RJ, Lye DC, McQuilten Z, Paterson DL, Owen Robinson J, Roberts JA, Scarborough M, Webb SA, Whiteway L, Tong SYC, Davis JS, Walls G, Goodman AL; SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee; SNAP Trial Group. Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clin Infect Dis. 2024 Oct 15;79(4):871-887. doi: 10.1093/cid/ciad666. PubMed 37921609 ↗
  • Mahar RK, McGlothlin A, Dymock M, Lee TC, Lewis RJ, Lumley T, Mora J, Price DJ, Saville BR, Snelling T, Turner R, Webb SA, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2023 Dec 6;24(1):795. doi: 10.1186/s13063-023-07718-x. PubMed 38057927 ↗
  • Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial. Lancet. 2026 Jul 11;408(10550):141-152. doi: 10.1016/S0140-6736(26)00761-0. Epub 2026 Jun 17. PubMed 42309115 ↗
  • Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group; Lee TC, Barina LA, Walls G, Goodman AL, Yahav D, Cheng MP, Bonten M, Bowen AC, Boyles T, Daneman N, Ekkelenkamp MB, Ghanem-Zoubi N, Hensgens MPM, Jager NGL, Kaasch AJ, Kouijzer IJE, Lewis RJ, Lumley T, Lye DC, McDonald EG, McKew G, McLean ARD, McMullan BJ, McQuilten ZK, Morpeth SC, Paterson DL, Roberts JA, Robinson JO, Saito H, Scarborough M, Ten Oever J, Turner RM, Tverring J, van Hal SJ, Webb SA, Whiteway LM, Arias CA, Henderson A, Heriot GS, Snelling TL, Afra K, Ali SS, Amit S, Anagnostou NA, Archuleta S, Aston SJ, Athan E, Baharav N, Bai AD, Barber BE, Baskaran A, Berkeley MMA, Best EJ, Bhilave NR, Bloomfield MG, Bond KA, Bostock J, Botheras CL, Boyd MA, Bradshaw SME, Briggs EJ, Britton PN, Campbell AJ, Carr BZ, Chancellor JA, Chen K, Cheong EY, Chew KL, Chia PY, Chomba R, Chong BSW, Clews CJN, Cohen JM, Commons RJ, Cutfield T, Daley P, Daniel DS, Davies J, De P, Denholm JT, Di Virgilio M, Dishon-Benattar Y, Dotel R, Duan EH, Easom N, Eliakim-Raz N, England MM, Fahmy M, Findlater AR, Flanagan KL, Foo EZJ, Foo H, Forster DP, Fralick M, Frazer JL, Gador-Whyte AP, Garnham K, German GJ, Ghosh N, Gisolf EH, Giulieri SG, Goulding SR, Grant JM, Gregson D, Grimwade KC, Grupper M, Guy SD, Gwee A, Hall VG, Hardy EJ, Harris DJ, Hatcher J, Hobbs MR, Holmes NE, Howden BP, Huggan PJ, Jennings ZA, Johnstone J, Juniper T, Kalimuddin S, Kamfose M, Kandel C, Kelly MJ, Kozak RA, Kumin M, Lamontagne F, Lau JSY, Lee IR, Lin RJ, Lindsay D, Llewelyn MJ, Longtin Y, Lother SA, Luey CE, MacFadden DR, Mahony AA, Malden C, Malhame I, Manning LA, Marks M, Martin LJ, Matthews GV, McGann PH, McMahon JH, Melon A, Menon V, Mertz D, Meyer MP, Molton JS, Mora JM, Moran E, Mortimer LM, Motaganahalli S, Muller MP, Munro APS, Murray FA, Murthy S, Nagendra V, Nel H, New DWJ, Nguyen V, Norton G, Norton KM, Nourse CB, Nye CJS, O'Callaghan K, O'Sullivan MVN, Ong SWX, Otu AA, Owen M, Papenburg J, Parkes LO, Paul M, Perez-Patrigeon S, Petersiel N, Petrella L, Pett SL, Pham D, Piazzese CJ, Poulin S, Rehak R, Rennert-May E, Richards AJ, Rogers BA, Sahng E, Salada B, Scheuerman O, Schneider K, Schulz TR, Schwartz KL, Simos PA, Singh H, Sinkeler FS, Smith S, Smith BJ, Smith SW, Somayaji R, Sommerville C, Song RXJ, Sowden DC, Stark MJ, Stone NRH, Strunk T, Sud A, Swe KP, Symons CR, Tan YE, Ten Doesschate T, Thien SY, Thomas A, Trad MA, Tramontana AR, Tsang JLY, Ulett K, Underwood J, van Welzen BJ, Vazquez-Grande G, Velasquez Reyes DC, Verberk JDM, Voss LM, Ward D, Webb RH, Whitmore TJ, Wieder-Finesod A, Wilson HL, Wilson EW, Wong HM, Wong She K, Wuerz T, Yamamura DL, Yeoh A, Yow BLH, Dymock M, Mahar RK, McGlothlin A, Marsh JA, Davis JS, Tong SYC. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia. N Engl J Med. 2026 Jun 18;394(23):2329-2339. doi: 10.1056/NEJMoa2506905. PubMed 42308484 ↗
  • Shah S, Clarke LG, Falcione BA, Shields RK, Smith BJ. Incidence and factors associated with rapid blood culture sterilization among patients receiving ertapenem combination therapy for MSSA bacteremia. Antimicrob Agents Chemother. 2026 Feb 4;70(2):e0130325. doi: 10.1128/aac.01303-25. Epub 2025 Dec 23. PubMed 41433510 ↗
  • Mahar RK, McGlothlin A, Dymock M, Barina L, Bonten M, Bowen A, Cheng MP, Daneman N, Goodman AL, Lee TC, Lewis RJ, Lumley T, McLean ARD, McQuilten Z, Mora J, Paterson DL, Price DJ, Roberts J, Snelling T, Tverring J, Webb SA, Yahav D, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2025 Feb 11;26(1):49. doi: 10.1186/s13063-024-08684-8. PubMed 39934879 ↗

Individual participant data

Plan to share: Yes — De-identified patient data

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: IPD and supporting information will be available 12 months after the publication of the primary results manuscript and will be available for a 10 year period.

Access criteria: All requests for data sharing must be accompanied by a SNAP data access request from, a study proposal with clear statement of aims and hypotheses, and a statistical analysis plan. All applications will be assessed by the SNAP Trial Steering Committee. Applications from investigators with suitable academic capability to conduct the proposed work will be given consideration. If a proposal is approved, a signed data transfer agreement will be required before data sharing.

Data sharing details ↗ · www.snaptrial.com.au

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Dec 2028, 81 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2021
First posted
Nov 30, 2021
StartActual
Feb 16, 2022
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05137119
Lead sponsor
University of Melbourne
Collaborators
Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, The Methodist Hospital Research Institute
Responsible party
Sponsor
First posted
Nov 30, 2021
Start date
Feb 16, 2022
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
May 6, 2026

Study contacts

Lauren Barina
Contact
lauren.barina@unimelb.edu.au
+61 (03) 8344 1623
Susan Goulding
Contact
susan.goulding@unimelb.edu.au
+61 (03) 8344 7799
Prof Steven Tong
study chair · University of Melbourne / Melbourne Health
Prof Joshua Davies
study chair · Menzies School of Research / Hunter New England Medical Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cefazolin · Penicillins · Penicillin Antibiotic · Penicillin G · Clindamycin · Vancomycin

Start the discussion